罗格列酮对2型糖尿病患者血清sVCAM-1水平的影响  

Effect of rosiglitazone on sVCAM-1 in type 2 diabetic patients

作　　者：徐茂锦[1] 叶江洪[2] 邹大进[1] 

机构地区：[1]第二军医大学附属长海医院,上海200433 [2]解放军第四一一医院,上海200081

出　　处：《海军医学杂志》2006年第4期298-300,共3页Journal of Navy Medicine

摘　　要：目的:研究罗格列酮对2型糖尿病患者血清可溶性血管细胞粘附分子-1(sVCAM-1)水平的影响及其作用机制。方法:用酶联免疫吸附(ELISA)法测定2型糖尿病患者罗格列酮治疗前后血清sVCAM-1水平并分析其与肿瘤坏死因子(TNF-α)、HbA1C、空腹血糖(FBG)等的关系。结果:2型糖尿病患者服用罗格列酮后血清sVCAM-1水平下降(P<0.01);sVCAM-1与TNFα、HbA1C呈正相关。结论:罗格列酮能够降低2型糖尿病患者血清sVCAM-1水平,其机制可能与HbA1C生成减少、TNFα水平降低有关。Objective： To study the effect of rcsiglitazone on sVCAM- 1 （serum level of ,soluble vascular cell adhesion molecule - 1） in type 2 diabetic patients. Methods： Serum level of sVCAM- 1 was measured by using ELISA before and after rosiglitazone intervention on type 2 diabetic patients and an analysis was made on the correlation between sVCAM- 1 and TNFα, HbA1C, FBG. Results： The serum levels of sVCAM - 1 decreased alter rosiglitazone intervention （P〈0.01） ;Results show that sVCAM- 1 is directly proportional to TNFa and HbA1C. Conclusion： Rosiglitazone could obviously decrease ,serum level of sVCAM - 1 in type 2 diabetic patients, and its mechanism might lie in the reduction of HbAIC and TNFa level.

关 键 词：2型糖尿病 可溶性血管细胞粘附分子-1 罗格列酮 

分 类 号：R589.1[医药卫生—内分泌]